Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1B | P36896 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309823 | 0.89 | MDM2 (0.33) | — | |
| SCHEMBL25839636 | 0.80 | ADORA3 (0.36) | MKNK2ADORA3ADORA2A | |
| SCHEMBL25839664 | 0.79 | ADORA3 (0.34) | ADORA3ADORA2A | |
| SCHEMBL25117793 | 0.78 | JAK2 (0.35) | TGFBR1JAK3BRD4ADORA3ADORA2A | |
| SCHEMBL25839410 | 0.76 | JAK2 (0.34) | MKNK2JAK3BRD4ADORA3ADORA2A | |
| SCHEMBL25117922 | 0.76 | JAK2 (0.36) | TGFBR1MKNK2ADORA3ADORA2AJAK2 | |
| SCHEMBL25117920 | 0.76 | JAK2 (0.36) | TGFBR1MKNK2ADORA3ADORA2AJAK2 | |
| SCHEMBL25117792 | 0.76 | JAK2 (0.35) | TGFBR1MKNK2BRD4ADORA3ADORA2A | |
| SCHEMBL25839421 | 0.76 | KDM4E (0.39) | MKNK2ADORA3ADORA2A | |
| SCHEMBL25839621 | 0.74 | KDM4E (0.38) | MKNK2ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219978-A1 | COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219978-A1 | COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF | BTK, SRC, YES1 | ACVR1B 3362/4885TGFBR1 829/4885ACVRL1 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.